Apoptosis-induced by TRAIL and TNF-α in human multiple myeloma cells is not blocked by Bcl-2

Cytokine

Volumn 11, Issue 12, 1999, Pages 1010-1019

  Gazitt, Yair ^a   Shaughnessy, Paul ^b   Montgomery, Willi ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Willford Hall Medical Center ^*  (United States)

Author keywords

Apoptosis; Bcl 2; Fas; TNF; TRAIL

Indexed keywords

FAS LIGAND; LIGAND; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033370411     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0536     Document Type: Article

References (45)

1. Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol. 16:1996;87-103.
2. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
3. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
4. Chinayan AM, Dixit VM. Portrait of an executioner: the molecular mechanism of FAS/APO-1 induced apoptosis. Semin Immunol. 9:1997;79-76.
5. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
6. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda M, Tsujimoto Y. Involvement of CPP32/Yama-like proteases in Fas-mediated apoptosis. Cancer Res. 56:1996;1713-1718.
7. Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain molecules that inhibit both CD95 and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem. 272:1997;9621-9624.
8. Beg AA, Baltimore D. An essential role for NF-κB in the prevention of TNF-α-induced apoptosis. Science. 274:1996;782-784.
9. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of JNK kinase and p38 kinase regulates cell survival in response to tumor necrosis factor α J Biol Chem. 273:1998;1032-1039.
10. Wiley SR, Schooley K, Smolak JP, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
11. Marsters SA, Sheridan JP, Donahue J, Pitti RM, Gray CL, Goddard AW, Bauer D, Ashkezazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Current Biol. 6:1996;1669-1676.
12. Mac Farlen M, Ahmed M, Srinivasula SM, Fernandez-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 272:1997;25417-25420.
13. Masters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Juan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo-2/TRAIL contains a truncated death domain. Current Biol. 7:1997;1003-1006.
14. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AW, Godowsi P, Ashkezazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
15. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:1997;815-818.
16. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Miashita T, Hovey RL, Huen D, Rickinson A, Veerapandian P, Krajewski S, Saito K, Reed JC. Evolutionary conservation of function among mammalian, avian, and viral homologs of the bcl-2 oncoprotein. DNA Cell Biol. 13:1994;679-692.
17. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res. 53:1993;4701-4714.
18. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood. 80:1992;879-886.
19. Reed JC, Kitada S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 5:1994;s61-s65.
20. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of bcl-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 8:1994;1960-1969.
21. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in human leukemia cell line. Blood. 81:1994;151-157.
22. Reed JC. Bcl-2 and programmed cell death. J Biol Chem. 124:1994;1-6.
23. Sentman CL, Shutter JR, Hokenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67:1991;879-888.
24. Iwai K, Miawaki T, Takizawa T, Konno A, Ohta K, Yachiet A, Seki H, Taniguchi N. Differential expression of bcl-2 and susceptibility to anti-Fas-induced cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood. 84:1994;1201-1208.
25. Munker, R, Lubbert, M, Yonehara, S, Tuchnitz, A, Mertelsmann, R, Wilmanns, W, 1995, Expression of the Fas antigen on primary human leukemia cells. Ann Hematol, 70, 15, 17.
26. Debatin K-M, Krammer PH. Resistance to APO-1 (CD95)-induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia. 9:1995;815-820.
27. Kondo, E, Yoshino, T, Yamadori, I, Matsuo, Y, Kawasaki, N, Minowada, J, Akagi, T, 1994, Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphoma. Am J Pathol, 145, 330, 336.
28. Rodriguez I, Matsuura K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminanat liver destruction but not rapid death induced by anti-Fas antibody injection. J Exp Med. 183:1996;1031-1036.
29. Strasser A, Harris AW, Huang D, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulates distinct pathways to lymphocyte apoptosis. EMBO J. 14:1995;6136-6147.
30. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
31. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol. 151:1993;621-627.
32. Tian E, Gazitt Y. The role of P53, bcl-2 and bax in dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol. 8:1996;719-726.
33. Hu W-X, Gazitt Y. Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol. 9:1996;375-381.
34. Tian E, Hu W-X, Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in multiple myeloma cell lines: a study with inducible bcl-2 transfection construct. Int J Oncol. 9:1996;165-169.
35. Gazitt Y, Rothenberg ML, Hilsenbeck S, Fey V, Thomas C, Montgomery W. Bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines. Int J Oncol. 13:1998;839-848.
36. Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone but not melphalan in multiple myeloma cell lines. Int J Oncol. 13:1998;397-405.
37. Gazitt Y, Hu W-X. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: A study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines. Int J Oncol. 12:1998;211-220.
38. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstien J. Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood. 84:1994;3063-3070.
39. Gazitt Y, Erdos GW. Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res. 54:1994;950-956.
40. Gazitt Y, Reading CC, Hofmann R, Wickrema A, Vesole DH, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G. Purified CD34+Lin-Thy+ cells do not contain myeloma cells. Blood. 86:1995;381-389.
41. Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science. 281:1998;1322-1325.
42. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas binding protein that activates JNK and apoptosis. Cell. 89:1997;1067-1076.
43. Sawamura M, Murakami H, Tsuchia J. Tumor necrosis-α and IL-4 in myeloma cell precursor differentiation. Leukemia Lymphoma. 21:1996;31-36.
44. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of IL-1 and tumor necrosis factor-alpha in human multiple myeloma. Br J Hematol. 74:1990;424-431.
45. Chauhan D, Pandey P, Ogata A, Teoh G, Treon SP, Urashima M, Kharbanada S, Anderson KC. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 15:1997;837-843.